英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • Abstract 2362: Preclinical efficacy and safety of M9140, a novel . . .
    The TOP1 inhibitor-based ADC M9140 caused strong antitumor efficacy with a tumor volume reduction of 74% and 88% as best response in two CRC PDX models where a maytansine-based CEACAM5 ADC was not effective
  • First-in-human trial of M9140, an anti-CEACAM5 . . . - ASCO Publications
    First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC) Background: CEACAM5 is a cell surface protein with limited expression in adult healthy tissues, but high expression in various adenocarcinomas, particularly in CRC ( 90% of pts)
  • Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) - ICH GCP
    The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2)
  • Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
    The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2)
  • Antibody-Drug Conjugate (ADC) - merckgrouponcology. com
    M9140 – CEACAM5 ADC M9140 is an investigational CEACAM5 ADC that is designed to deliver a cytotoxic topoisomerase 1 (TOP1) inhibitor payload to CEACAM5-expressing tumor cells 5-7 The TOP1 inhibitor payload enters the nucleus and disrupts DNA replication and repair, thereby killing CEACAM5-expressing tumor cells 5-7 The payload can also
  • [PDF] First-in-human trial of M9140, an anti-CEACAM5 antibody drug . . .
    M9140 is the first anti-CEACAM5 ADC with a topoisomerase 1 inhibitor (Top1i) payload (exatecan) The ß-glucuronide linker connecting the M9140 antibody backbone to the payload is highly stable in circulation (drug-to-antibody ratio=8) In preclinical models, M9140 has demonstrated strong potency, antitumor activity, and a bystander effect
  • CONCLUSIONS - cslide. ctimeetingtech. com
    • M9140 is an anti-CEACAM5 ADC that selectively delivers a cytotoxic Top1 inhibitor payload (exatecan) • M9140 demonstrated high potency, strong antitumour activity, and bystander effect in preclinical models2 • Preliminary data from the dose escalation part of the ongoing PROCEADE-CRC-01 study (NCT05464030) showed encouraging
  • First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate . . .
    study Conclusions: M9140 demonstrated encouraging activity in heavily pretreated pts with advanced CRC, with a manageable and predictable safety profile Contrary to approved ADCs with Top1i payloads, no ILD or ocular toxicities were observed Evaluation of M9140 in mCRC continues in the dose expansion part of this study


















中文字典-英文字典  2005-2009